Advertisement
Advertisement
U.S. markets open in 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.30+0.08 (+0.61%)
At close: 04:00PM EDT
12.80 -0.50 (-3.76%)
Pre-Market: 08:46AM EDT
Advertisement
Sign in to post a message.
  • J
    Jerry
    I love how no one knows about this company but eddy. I have been buying since last year and every month buy more. If this company was based in the U.S with their pipeline, would be valued at 2-4 times what it is now. Raise my cost basis with my newer buys, but still a awesome value here. 2019 will be a big year. 2018 may be the last year it is not on the smart money radar. I hope.
  • J
    Jerry
    With such high volume and 17% gain on Wednesday, I expect some news soon. A approval or some great top line news from their vast pipeline. If a USA company had their Innovation Platform (IP) and Commercial Platform (CP) HCM would be trading at $150. Just look at their pipeline and what is coming the next 1-3 years. Since this is a Chinese company, I value their IP at 6 Billion and their CP at 1 Billion on the conservative side. So very undervalued here even with the 17% gain Wednesday. Great value here on potential massive growth.
  • e
    eddy
    Once again this is a great opportunity
  • J
    James
    Looks like we should see a rise on volume. People are starting to see there is no negative side to this secondary.
  • L
    Lioness
    $JD conversation
    Comments by AQR are deceiving. The stocks being considered for delisting are $BGNE, $YUMC, $ZLAB, $ACMR and $HCM,
  • J
    James
    It looks like a lot of the algorithm selling happened when the secondary offering happened. What the holograms failed to account for though was that this is a sale of ADR's by the Maj shareholder.... Just a sale, not a split..... All it says is that the major shareholder needs cash.
  • D
    David
    CKHH disposal complete, so they now own 49.86%, taking them below 50%. Overhang now gone or going fast. Maybe we can get back to a sensible valuation.....TD values the Company at $38.55/ADS
  • Y
    YANG
    Fruquintinib was approved by cFDA yesterday.
  • M
    Mike
    I wrote this in November when the position was trading at 19.00 but it is till applicable.

    https://seekingalpha.com/instablog/32746315-michael-england/5371294-hcm-riding-wave
    HCM- Riding The Wave - Michael England
    seekingalpha.com
  • D
    David
    Trinity Delta issued an updated research note on Thursday

    https://www.trinitydelta.org/research-notes/timing-is-right-for-a-hong-kong-debut/

    I continue to Buy
  • K
    Kenneth
    Can someone explain to me what this secondary offering is all about? Confused with limited press releases
  • D
    David
    This tells you all you need to know about the Company and its brilliant Management Team. This will be a $25bn mcap Company in the next 5 years in my view

    https://www.standard.co.uk/business/anthony-hilton-the-remarkable-tale-of-chimed-s-growth-a3661656.html
    You could have bought shares in Hutchison China MediTech, or Chi-Med, listed on AIM — and on Nasdaq in the US — for 30p in the aftermath of the financial crash in 2008. When this column drew attention to the company in March they were changing hands
    You could have bought shares in Hutchison China MediTech, or Chi-Med, listed on AIM — and on Nasdaq in the US — for 30p in the aftermath of the financial crash in 2008. When this column drew attention to the company in March they were changing hands
    www.standard.co.uk
  • D
    David
    Fantastic reaction to the HK listing. At last with Asian investors omn board we will get a proper valuation like Beigene and Innovent. See ya'll at $2bn in 1 to 2 years time.
  • J
    Jerry
    https://finance.yahoo.com/news/chi-med-announces-phase-iii-070000682.html

    Can't win them all, still valuable for company moving forward. Pipeline vast.
    – Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
    – Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
    finance.yahoo.com
  • D
    David
  • e
    eddy
    Buy while it’s low
  • C
    Crescent
    Could have bought this a few weeks ago at $23 when folks misread the news...heading to $30
    Bullish
  • e
    eddy
    Hidden gem with real money supporting it
  • D
    David
    Massive ate stage pipeline news due in next couple of weeks

    1. Initiation of a global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

    2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling

    3. 2nd Line PFS data for Savo/tagrisso due to be released by end 2018. CH has said this data is very encouraging.
Advertisement
Advertisement